Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) have been given a consensus rating of "Moderate Buy" by the six research firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $10.80.
A number of equities analysts have issued reports on RGLS shares. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Regulus Therapeutics in a research note on Monday, November 11th. StockNews.com raised shares of Regulus Therapeutics to a "sell" rating in a research report on Tuesday, September 17th.
Read Our Latest Stock Analysis on RGLS
Regulus Therapeutics Price Performance
Shares of NASDAQ RGLS traded down $0.08 during mid-day trading on Friday, hitting $1.41. The company had a trading volume of 289,994 shares, compared to its average volume of 273,282. Regulus Therapeutics has a 12 month low of $1.08 and a 12 month high of $3.79. The firm has a market cap of $92.36 million, a P/E ratio of -1.32 and a beta of 1.60. The business's 50-day simple moving average is $1.54 and its 200-day simple moving average is $1.60.
Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.03). As a group, sell-side analysts predict that Regulus Therapeutics will post -0.88 EPS for the current year.
Hedge Funds Weigh In On Regulus Therapeutics
Hedge funds have recently made changes to their positions in the stock. Creative Planning bought a new stake in Regulus Therapeutics in the third quarter worth approximately $26,000. SG Americas Securities LLC purchased a new position in shares of Regulus Therapeutics during the third quarter valued at approximately $33,000. Jane Street Group LLC purchased a new position in shares of Regulus Therapeutics during the third quarter valued at approximately $46,000. JPMorgan Chase & Co. boosted its position in Regulus Therapeutics by 193.4% in the third quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company's stock worth $124,000 after purchasing an additional 52,059 shares during the last quarter. Finally, Barclays PLC boosted its position in Regulus Therapeutics by 285.2% in the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company's stock worth $132,000 after purchasing an additional 62,549 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors.
About Regulus Therapeutics
(
Get Free ReportRegulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.
See Also
Before you consider Regulus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regulus Therapeutics wasn't on the list.
While Regulus Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
